Findings

What do systematic reviews say?

189 questions · 192 findings · 50 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 34 · 17.7%GRADE not reported 22 · 11.5%Very low 45 · 23.4%Low 54 · 28.1%Moderate 34 · 17.7%High 3 · 1.6%

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Histological improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 10 mg/kg vs mepolizumab 0.55 mg/kg

Withdrawals due to adverse events · active EoE pediatric patients

It is very uncertain whether mepolizumab 10 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.63 [0.12, 3.38]
1 study · 39 participants
Very low

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Clinical improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Clinical improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Histological improvement (dichotomous) · active EoE pediatric patients

It is very uncertain whether mepolizumab 2.5 mg/kg changes histological improvement at 12 weeks (dichotomous) compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 2.14 [0.79, 5.79]
1 study · 39 participants
Very low

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Histological improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (dichotomous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Endoscopic improvement (continuous) · active EoE pediatric patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mepolizumab 2.5 mg/kg vs mepolizumab 0.55 mg/kg

Withdrawals due to adverse events · active EoE pediatric patients

It is very uncertain whether mepolizumab 2.5 mg/kg changes withdrawals due to adverse events at 8 weeks compared with mepolizumab 0.55 mg/kg (very low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.32 [0.04, 2.79]
1 study · 39 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Improvement in symptoms · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Adverse events · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Endoscopic improvement (dichotomous) · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

pH indices ‐ not measured · GORD in children over 1 year of age

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chloral hydrate oral (100 mg/kg or 75 mg/kg) vs midazolam

Proportion of children who successfully completed neurodiagnostic procedure without interruption by the child awakening · children undergoing neurodiagnostic procedures

The review found no eligible studies for this question.

1 finding from 1 review

Chloral hydrate as a sedating agent for neurodiagnostic procedures in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chloral hydrate oral (100 mg/kg or 75 mg/kg) vs midazolam

Proportion of children who required a further dose of either the same sedative agent or the addition of a different sedative agent · children undergoing neurodiagnostic procedures

The review found no eligible studies for this question.

1 finding from 1 review

Chloral hydrate as a sedating agent for neurodiagnostic procedures in children 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Chloral hydrate oral (100 mg/kg or 75 mg/kg) vs midazolam

Time to adequate sedation (minutes or as measured by specific validated scales such as the Ramsay Sedation Score) · children undergoing neurodiagnostic procedures

1 finding from 1 review

Chloral hydrate as a sedating agent for neurodiagnostic procedures in children 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Moderate

Chloral hydrate oral (100 mg/kg or 75 mg/kg) vs midazolam

Proportion of children with inadequate level of sedation (Ramsay score below 4) · children undergoing neurodiagnostic procedures

Chloral hydrate oral (100 mg/kg or 75 mg/kg) probably leads to lower proportion of children with inadequate level of sedation (Ramsay… compared with midazolam (intranasal 0.2 mg/kg or oral 0.5 mg/kg) (moderate certainty).

1 finding from 1 review

Chloral hydrate as a sedating agent for neurodiagnostic procedures in children 2021 · Cochrane Headline outcomes only
RR 0.11 [0.03, 0.44]
1 study · 60 participants
Moderate

Chloral hydrate oral (100 mg/kg or 75 mg/kg) vs midazolam

Proportion of children who had sedation failure after 1 dose of sedative agent · children undergoing neurodiagnostic procedures

Chloral hydrate oral (100 mg/kg or 75 mg/kg) showed no clear difference in proportion of children who had sedation failure after 1 dose of… compared with midazolam (intranasal 0.2 mg/kg or oral 0.5 mg/kg) (low certainty).

1 finding from 1 review

Chloral hydrate as a sedating agent for neurodiagnostic procedures in children 2021 · Cochrane Headline outcomes only
RR 0.17 [0.02, 1.12]
1 study · 33 participants
Low